

PHYLOGICA

BREAKTHROUGH PEPTIDE THERAPEUTICS

Finance News Network Interview with CEO

PERTH, Australia, 20th September 2017: Phylogica Limited (ASX:PYC) (**Phylogica** or the **Company**), developer of a leading intracellular drug delivery platform technology, is pleased to advise that a video recording conducted by Finance News Network with CEO Stephanie Unwin has been made available [here](#).

In the interview, Stephanie Unwin discusses the Company's unique drug delivery platform, highlights and progress made during FY17, and strategy looking forward.

The interview will also be made available on the Phylogica website.

ENDS

For further information, please contact:

INVESTORS

Stephanie Unwin
CEO
stephanieu@phylogica.com
0411 132 287

MEDIA

Ben Walsh
WE Buchan
bwalsh@buchanwe.com.au
0411 520 012

About Phylogica

Phylogica Limited (ASX: PYC) is a biotech company focused on commercialising its intracellular drug delivery platform and panning its Phylomer libraries to identify drug cargoes for development against a wide range of disease targets. Phylogica controls access to the world's most structurally diverse source of peptides called Phylomers, which have the ability to act as effective drug delivery agents and drug cargoes, penetrating cell walls to reach previously 'undruggable' targets across a range of disease types. Phylogica's platform of proprietary cell penetration peptides is showing promise in delivering a diverse range of drug cargoes into cells, and the company's lead asset program has identified a phylomer which

can inhibit Myc, a protein responsible for the regulation of cancer cell growth. The company has collaborations with several pharmaceutical companies including Roche, Medimmune, Pfizer, Janssen and Genetech.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Phylogica's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and Phylogica's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. Phylogica undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by Phylogica. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 9384 3284 | Fax: +61 8 9284 3801

www.phylogica.com

Phylogica Ltd

ABN 48 098 391 961